Ftse Mib
35.390,52
-0,06%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.756,33
2,33%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Calliditas Therapeutics Ab (0A5R) Calliditas Therapeutics Ab (0A5R) Notizie

0A5R

Calliditas Therapeutics Ab (0A5R)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0A5R
DataOraFonteTitoloSimboloCompagnia
18/08/202310:21PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
17/08/202307:29PR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
15/08/202310:52PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
13/07/202308:20PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
21/06/202310:12PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
30/05/202316:18PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
16/05/202307:17PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202315:01PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
28/04/202310:54PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
27/04/202304:40PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
31/03/202317:24PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
13/03/202304:15PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
23/02/202307:41PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/02/202309:46PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
31/01/202308:22PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
30/12/202209:03PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
21/12/202204:08PR Newswire (US)Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022LSE:0A5RCalliditas Therapeutics Ab
13/12/202209:04PR Newswire (US)Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in JapanLSE:0A5RCalliditas Therapeutics Ab
09/12/202208:10PR Newswire (US)Calliditas to host fireside chat with its China commercial partner, Everest MedicinesLSE:0A5RCalliditas Therapeutics Ab
15/11/202208:45PR Newswire (US)Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPALSE:0A5RCalliditas Therapeutics Ab
14/11/202207:13PR Newswire (US)Calliditas Therapeutics: Interim Report Q3, 2022LSE:0A5RCalliditas Therapeutics Ab
07/11/202209:15PR Newswire (US)Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment LandscapeLSE:0A5RCalliditas Therapeutics Ab
21/10/202210:27PR Newswire (US)Calliditas Therapeutics' nomination committee composition for the AGM 2023LSE:0A5RCalliditas Therapeutics Ab
19/10/202216:09PR Newswire (US)Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
20/09/202215:29PR Newswire (US)Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
18/08/202207:18PR Newswire (US)Calliditas Therapeutics: Interim Report Q2, 2022LSE:0A5RCalliditas Therapeutics Ab
15/07/202217:19PR Newswire (US)European Commission approves Kinpeygo® for adults with primary IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
11/07/202213:00PR Newswire (US)Calliditas announces additions to the management teamLSE:0A5RCalliditas Therapeutics Ab
29/06/202200:27PR Newswire (US)Calliditas Therapeutics establishes a U.S. At-the-Market ProgramLSE:0A5RCalliditas Therapeutics Ab
19/05/202214:44PR Newswire (US)Calliditas receives positive CHMP opinion in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0A5R

La tua Cronologia

EU
R684S
R684S
NYSE
CLNY.PRB
Colony Financial Inc.
COIN
CNEXGBP
CNEXCHANGE
BIT
UI530B
Unicredit Bank
USOTC
MLGCF
M3 Metals (QB)
BIT
UB3JUJ
UniCredit Bank
BIT
PSRW
Invesco FTSE RAFI All Wo...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network